Calcimimetics in peritoneal dialysis patients.

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Secondary hyperparathyroidism (SHP) and mineral metabolism (MM) changes are common in chronic kidney disease (CKD) patients on dialysis.
• Peritoneal dialysis (PD) patients exhibit a higher prevalence of adynamic bone disease (ABD) and more frequent vitamin D deficiency compared to hemodialysis (HD) patients.
• Current therapies for SHP and MM changes have limitations in simultaneously controlling all parameters.

Purpose of the Study:

• To evaluate the efficacy and safety of Cinacalcet in managing SHP and MM disturbances in PD patients.
• To compare the therapeutic approach for SHP and MM changes in PD versus HD patients.
• To assess the potential differences in the need for potent SHP medications like Cinacalcet between PD and HD populations.

Main Methods:

• Review of existing literature on Cinacalcet use in PD patients.
• Comparison of outcomes in PD patients treated with Cinacalcet versus standard therapy (ST).
• Analysis of mineral metabolism parameters (PTH, calcium, phosphorus) and safety profiles.

Main Results:

• Cinacalcet demonstrated a significant reduction in PTH levels in PD patients, similar to findings in HD patients.
• Associated decreases in calcium and phosphorus were observed, though phosphorus reduction was less pronounced in PD patients compared to HD patients.
• The safety and tolerability profile of Cinacalcet in PD patients mirrored that seen in HD patients, with gastrointestinal symptoms being most common.

Conclusions:

• While Cinacalcet is effective in reducing PTH and improving MM parameters in PD patients, its necessity may be lower compared to HD patients.
• PD patients often have better phosphate control and higher rates of vitamin D deficiency, potentially reducing the need for aggressive SHP therapies.
• Individualized therapeutic strategies for SHP and MM management are crucial for PD patients, considering their unique metabolic profiles.